A toxin produced by bacteria found in dirty water kills off immune cells in the lining of the colon, meaning people whose guts are colonised by these bacteria are much more likely to develop a ...

Investigational rosnilimab was safe and well-tolerated; however, it did not meet the primary endpoint of the mean change from baseline in the modified Mayo Score (severity of ulcerative colitis, mMS) ...

AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis (UC) after the PD-1 agonist flunked a phase 2 study. The San Diego-based biopharma assessed rosnilimab in the midstage study ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Subcutaneous guselkumab induction and maintenance ...

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes inflammation of the colon, and leads to symptoms such as fatigue, abdominal pain, and cramping. There is currently no cure ...

A once-daily pill for ulcerative colitis has delivered strong results in a clinical trial, easing symptoms even in patients for whom other treatments had failed and raising hopes for a safer, more ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative ...

The FDA approved the TNF-alpha inhibitor golimumab (Simponi, Johnson & Johnson) to treat children with moderately to severely active ulcerative colitis (UC) weighing at least 15 kg. Of the more than 1 ...

Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease (IBD) and, in doing so, achieved a first for the IL-23 inhibitor drug class.